(MedPage Today) — An SGLT2 inhibitor helped improve metabolic dysfunction-associated steatohepatitis (MASH) in people with or without type 2 diabetes, a randomized trial in China found.
In 154 adults with biopsy-diagnosed MASH, improvement without…
Source link : https://www.medpagetoday.com/gastroenterology/generalhepatology/115913
Author :
Publish date : 2025-06-04 22:30:00
Copyright for syndicated content belongs to the linked Source.
